G
astroesophageal reflux disease (GERD), defined as heartburn and/or regurgitation on at least 1 day a week, is a very widespread condition. 1 Gastroesophageal reflux impairs the mucosal barrier in the distal esophagus, allowing chronic exposure of the epithelial cells to diverse injury, inducing chronic inflammation and inducing chronic inflammation. In turn, chronic inflammation may play a crucial role in the progression from reflux-related intestinal metaplasia or Barrett's esophagus to esophageal carcinoma. 2 The prevalence of GERD varies throughout the world for unknown reasons, but genetic differences, differences in Helicobacter pylori prevalence, and lifestyle factors such as obesity might have an influence. The prevalence is lowest in East Asia (2.5% to 9.4%) and higher in Central (7.6% to 19.4%) and Western Asia (12.5% to 27.6%). The highest population-based prevalence is reported from Europe (23.7%) and the United States (28.8%). 3 The mainstay of pharmacological therapy for GERD is gastric acid suppression. Proton pump inhibitors (PPIs) such as omeprazole, lansoprazole, pantoprazole, rabeprazole, and esomeprazole are the most widely used drug type in this regard and are superior to histamine-2 receptor antagonists in healing erosive esophagitis and achieving symptomatic relief. 4 Chronic treatment with PPIs severely counteracts the production of gastric acid, thus raising a number of theoretical problems including overgrowth of bacteria in the stomach and the small intestine. 5 H. pylori status appears to affect the degree of overall bacterial colonisation in patients taking PPIs, with subjects taking PPIs and affected by H. pylori showing a greater degree of bacterial overgrowth than H. pylori-negative individuals.
H. pylori is a gram-negative bacillus that colonises the stomachs of approximately 50% of individuals worldwide. H. pylori has been studied more intensely than any other stomach pathogen. Although H. pylori is the major pathogenic factor of chronic gastritis and peptic ulcer and is one of the risk factors for gastric adenocarcinoma and mucosa-associated lymphoid tissue lymphoma, 6 ,7 the relationship between H. pylori infection and gastric diseases still remains unclear.
It is well known that the upper gastrointestinal tract normally harbours <10 3 microorganisms per millilitre (mL) of fluid 8 and "bacterial overgrowth" has been defined as counts higher than 10 5 cells/mL of fluid. There are 3 possible ways for bacteria to reach the gastric lumen: they can be ingested through food or originate from the oropharyngeal cavity, otherwise migrate from the small or large bowel and enter the stomach by enterogastric reflux.
The more the intragastric pH rises, the more the survival of bacteria increases to the point of being cultivated from the gastric juice. 9 The colonisation of the stomach is related to the intraluminal pH value and to the time that bacteria spend in an environment at pH > 3.8. 10 If the pH is <4.0 for a few hours a day, bacterial growth is generally inhibited. In any case, enteric pathogens show variable gastric acid pH susceptibility and acid tolerance levels. 11 In early studies of achlorhydria due to pernicious anaemia, microbiological evaluation of gastric juice showed that coliforms, normally present in the gut microbiota, were commonly found. 12, 13 However, when achlorhydria is caused by acid suppressant drugs, the duration of this condition is shorter and the bacterial overgrowth principally consists of gram-positive organisms more closely resembling the mouth and oropharynx flora. 14, 15 Growth on the gastric mucosal surface may be detected in about 50% of patients after longterm treatment with any type of effective antisecretory drug. 15 Prolonged gastric acid suppression, as in GERD patients, is associated with a larger risk of bacterial overgrowth and a higher incidence of faecal-type bacteria.
Through multiple mechanisms, PPIs appear to increase susceptibility to the following bacterial enteropathogens: Salmonella, Campylobacter jejuni, invasive strains of Escherichia coli, vegetative cells of Clostridium difficile, Vibrio cholera, and Listeria. 16 E. coli is a gram-negative, rod-shaped bacterium commonly found in the lower intestine of warmblooded organisms. As a part of the normal gut microflora, this microorganism colonises the gastrointestinal tract of animals and humans within a few hours after birth. 17 However, some pathogenic strains have acquired the ability to induce chronic inflammation and/or produce toxins, such as cyclomodulin, which could participate in the carcinogenesis process, especially in the colorectal tract. 18 Virulent strains of E. coli can cause gastroenteritis and urinary tract infections. In rare cases, some strains are also responsible for haemolytic-uraemic syndrome, peritonitis, septicaemia, and gramnegative pneumonia. 19 The significance of bacterial overgrowth during acid suppressive therapy depends on the ability of the bacterial flora to contribute directly or indirectly to any pathologic condition. It is well known that bacterial overgrowth is able to induce chronic inflammation and damage to the mucosal cells of infected individuals, driving gastric malignancies and cancer. 20 Gastric cancer is one of the most common malignancies worldwide. Enterococcus faecalis can colonise achlohydric stomachs, thus inducing an oxidative phosphorylation-independent intracellular reactive oxygen species response and damaging the mitochondrial genome in gastric cell culture. Such bacteria are also able to cause an NF-kB inflammatory response as well as impaired DNA damage response and cell cycle control gene expression. 20 The primary hypothesis of gastric carcinogenesis is centred on the evidence that bacterial overgrowth results in the production of nitrite from nitrate, with subsequent production of carcinogenic N-nitroso compounds. 21 In any case, it is generally assumed that environmental and dietary factors, H. pylori infection, and genetic factors contribute to the pathogenesis of gastric cancer. Furthermore, H.
pylori is closely related with gastric cancer, although whether other intragastric flora facilitate or inhibit the effect of H. pylori in gastric cancer development remains unclear and very few studies have examined this aspect. 22 In addition to the correlation between H. pylori and carcinogenesis, in H. pylori-negative patients who take PPIs after a 5-year follow-up, only 4% develop moderate to severe corpus gastritis. In comparison, the incidence of gastritis in the PPI-treated H. pylori-infected patients increases from 59% to 81% and atrophy from 0% to 31%. 23 One open question is whether the 4% incidence of gastritis in the H. pylori-negative PPI cohort could be regarded as evidence that bacterial overgrowth induces gastritis.
Furthermore, it has been suggested that reduced gastric acidity could predispose to enteric infection and, since 1934, bacillary and amoebic dysentery has been shown to occur more commonly in people with achlorhydria. 24 It has also been demonstrated that long-term PPI users have a 2.6 RR for C. difficile-associated diarrhoea. 25 Uncommon adverse effects of chronic treatment with PPIs include rebound acid hypersecretion syndrome, fragility fractures, interstitial nephritis, electrolyte problems, pneumonia, enteric infection, and vitamin B12 deficiency. 26 Three large case control studies involving up to 360,000 participants and 7 years of follow-up have demonstrated a 16% to 50% increased risk of pneumonia in PPI users. [27] [28] [29] In terms of bacterial overgrowth in the upper gastrointestinal tract induced by chronic treatment with a PPI drug, and its direct involvement in the onset and development of various pathologic conditions, a substantial challenge is represented by the possibility of restoring the gastric barrier, at least partially, through supplementation with specific beneficial bacteria to be taken orally.
For example, in vivo and in vitro studies based on animal models have found that some probiotics including Lactobacillus and Bifidobacterium can prevent the adhesion, colonisation, and growth of H. pylori in gastric mucosa. 30, 31 A previous pilot study by Del Piano et al 32 assessed the extent of gastric bacterial overgrowth in subjects taking PPIs either for 3 to 12 months (short-term) or for >12 months (long-term), focusing also on the composition of the microbiota found in the stomach and the duodenum. A parallel evaluation of the concentrations of some important microbial intestinal genera was also performed, thus confirming a significant proliferation of yeasts, moulds, enterococci, E. coli, and total coliforms compared with the control population. This study also demonstrated the ability of the 4 selected lactobacilli, namely L. rhamnosus LR06 (DSM 21981), L. pentosus LPS01 (DSM 21980), L. plantarum LP01 (LMG P-21021), and L. delbrueckii subsp. delbrueckii LDD01 (DSM 22106), given in association with N-acetylcysteine, to colonise the stomach and the duodenum, at least temporarily, thus reducing the bacterial overgrowth normally found in subjects undergoing longterm chronic treatment with PPIs. 32 This study was undertaken firstly to confirm and extend the data previously collected in a larger number of subjects chronically treated with PPIs, and to correlate the intake of such drugs with the incidence of H. pylori infection. A second important aim was the evaluation of the effectiveness of an association of the same four lactobacilli used in the previous study, L. rhamnosus LR06, L. pentosus LPS01, L. plantarum LP01, and L. delbrueckii subsp. delbrueckii LDD01, in the restoration of the gastric physiological barrier and the possible counteraction of bacterial overgrowth.
METHODS

Study Design
A total of 65 subjects (25 males, 40 females) voluntarily enrolled in the study, with enrolment taking place between March and June, 2013.
Eligible subjects were selected according to the following exclusion criteria: age younger than 18 years, ongoing pregnancy or lactation, severe cognitive deficits, severe chronic degenerative conditions, previous abdominal surgery, diverticulitis, immunodeficiency states, intestinal infections, concomitant organic bowel disease, treatment with antibacterial agents, or glucocorticoids or other products containing lactobacilli or bifidobacteria in the previous 2 months. 33 Informed written consent was obtained from each subject. This study was carried out in accordance with the Helsinki Declaration (2000) of the World Medical Association.
Subjects were then divided into 2 groups. In detail, 29 subjects were being treated with PPIs for at least 3 months (group A), whereas 36 subjects were enrolled as control population (group B).
Subjects in group A were instructed to continue therapy with their specific PPI drug at the same dose for the entire duration of the study.
Assessment of H. pylori Infection
The presence of an active infection by H. pylori was detected through histopathology evaluation of antrum biopsies. Diagnostic methods for H. pylori infection are usually classified as invasive and noninvasive. 34 Histopathology can be regarded as accurate as the PCR of biopsy. Gastroscopies were performed at the Gastroenterology Department of Maggiore della Carita`Hospital in Novara. In detail, gastric biopsy specimens were immersed in 10% formalin and fixed in paraffin. Sections were stained by hematoxylin and eosin and modified Giemsa. 35 The stained sections were randomly renumbered before examination by observer and were assessed separately without knowledge of previous results or of the proportions of positive versus negative cases.
Enumeration of Specific Bacterial Groups in Gastric Juice
Gastric juice was sampled at the Maggiore della CaritaH ospital (Novara, Italy) during a gastroscopy on patients after they had fasted for at least 12 hours. Gastric juice samples for the enumeration of specific bacterial groups were collected in sterile plastic containers previously filled with 10 mL of Amies transport liquid (BD Italia, Milan, Italy). All material was stored at 41C and delivered to the laboratory (Biolab Research, Novara, Italy) within 24 hours after collection. Samples were processed as soon as received by the laboratory.
The weighed samples were transferred to a sterile container (Stobag), diluted with Amies liquid to achieve 1:10 wt/vol and homogenised in a Stomacher for 4 minutes at 230 rpm. Samples were then decimally diluted using sterile saline and for each different bacterial group) was plated on specific cultural agarised media. Lower dilutions were used in group B because the bacterial counts were expected to be significantly lower than in the group treated with PPIs.
For total viable cells, the nonselective medium LAPTg was used, 36 whereas the selective count of total Lactobacillus was performed on Rogosa Acetate Agar medium (Oxoid, Milan, Italy). 37 Total coliforms were selectively counted on Petrifilm CC [3 M, Segrate (MI), Italy], 38 whereas SRB were enumerated using tryptose-sulfitecycloserine (Sigma-Aldrich, Milan, Italy). 39 All plates seeded with lactobacilli were incubated for 48 to 72 hours at 371C under anaerobic conditions (GasPak system) with Anaerocult A kits (Merck Millipore, Darmstadt, Germany), whereas LAPTg plates were incubated in aerobic conditions for 24 to 48 hours at 371C. Total coliforms were incubated in aerobic conditions at 371C for 24 hours, whereas SRB were incubated in anaerobiosis at 461C for 24 hours.
Assessment of the Efficacy of a Formulation Containing Lactobacilli
The subjects in the group treated with PPIs with a concentration of total bacteria in the gastric juice higher than 10 5 cells/mL were selected for an intervention study using the 4 specific lactobacilli L. rhamnosus LR06 (DSM 21981), L. pentosus LPS01 (DSM 21980), L. plantarum LP01 (LMG P-21021), and L. delbrueckii subsp. delbrueckii LDD01 (DSM 22106) administered in the form of a chewable tablet. In particular, the formulation contained 30 mg each of the 3 strains L. rhamnosus LR06, L. pentosus LPS01, and L. plantarum LP01, corresponding to 3Â10 9 CFU/strain/dose, 10 mg of the microorganism L. delbrueckii subsp. delbrueckii LDD01, corresponding to 1Â 10 9 CFU/dose, and 1.10 g of potato maltodextrin. The total number of viable cells per chewable tablet was 10 billion (10Â 10 9 CFU). Subjects were instructed to consume 1 chewable tablet every day in the morning on an empty stomach, at least 30 minutes before a meal. The duration of this supplementation treatment was 15 days.
At d 15 gastric juice samples for the enumeration of the same microbial groups as baseline were collected and analysed as previously described. The presence of H. pylori was also evaluated following the same protocol described above.
Probiotic strains in the final formulation used in this study were manufactured and provided by Probiotical Ltd., Novara, Italy.
Statistical Analysis
All values relating to the concentration of the total bacterial population and specific bacterial groups in the gastric juice samples are expressed as a mean number of viable cells/mL ± SD (m ± SD). Results for the H. pylori detection are expressed as positive (pos), negative (neg), not evaluated (n.e.), or uncertain (?).
Paired and unpaired t test statistical analyses were used to weigh the results and compare them between d 0 and d 15 in group A (paired) and at d 0 between the 2 groups (unpaired). Differences were considered significant at Pr0.05.
RESULTS
Assessment of H. pylori Infection
All 65 subjects underwent gastroscopy at baseline (d 0 ), whereas group A was also subjected to gastroscopy at the end of supplementation with lactobacilli (d 15 ) with the aim of detecting possible H. pylori infection. No dropouts were recorded, as the preparation was very well tolerated and accepted by each participant in group A enrolled for the second part of the trial, involving treatment with selected lactobacilli.
No significant correlation was established between the presence of H. pylori and PPI intake (Tables 1a, 1b) . In group A, the number of positive results was 6 at baseline, whereas in the control group, 9 subjects had a positive outcome for this parameter. Eighteen patients were negative in group A compared with 24 subjects in the control group (P = 0.504). No significant differences were recorded at the end of supplementation with the 4 lactobacilli in group A.
Enumeration of Specific Bacterial Groups in the Gastric Juice
The baseline quantification of specific microbial groups (log 10 CFU/mL of gastric juice, PPIs group vs. control) showed significant differences as regards total bacteria (8.35 vs. 3.95, P < 0.001), total coliforms (4.98 vs. 2.35, P < 0.001), and total lactobacilli (3.85 vs. 2.20, P = 0.005) (Table 2a) . Sulphite-reducing bacteria (SRB) showed a difference as well but not to a statistically significant extent (5.71 vs. 2.28, P = 0.065).
After 15 days of treatment with the 4 lactobacilli, the quantification of bacterial groups gave the following results: total bacteria 7.91 versus 8. (Table 2b) .
It is interesting to note that, in the control group, there is a moderately higher percentage of gastric microbiota consisting of lactobacilli (9.80%) at baseline compared with subjects taking PPIs for at least 3 months (0.06%) ( Table 2c ). As could be expected, after 15 days of supplementation with lactobacilli, the percentage of this genus in the microbiota was higher than 20%.
DISCUSSION
The human stomach is a formidable barrier to orally ingested microorganisms and was long thought to be sterile.
The discovery of H. pylori, a carcinogenic bacterial pathogen that infects the stomach mucosa of nearly half of the world's population, has progressively induced a major paradigm shift in our perception of the stomach as an ecological niche for bacteria. 40 In evolutionary terms, gastric acid has applied selective pressure on bacterial pathogens, and most bacteria capable of causing gastrointestinal disease have developed some mechanisms to reduce their sensitivity to gastric acid. 41 Today, the involvement of H. pylori in active chronic gastritis, its association with gastroduodenal ulcers, and its recognised role as a risk factor for the development of gastric cancer are well documented. 42 There are many schemes for treating H. pylori infection. However, no optimal treatment has been defined, and there is no antibiotic treatment that can eradicate the problem. 43 It has been hypothesised that probiotics compete directly with H. pylori by interfering with its adherence or by producing antimicrobial molecules. The efficacy of L. reuteri species in H. pylori eradication therapy has been investigated.
One 44 A recent meta-analysis examined whether an association of a Lactobacillus and a Bifidobacterium could improve H. pylori eradication rates and reduce side effects. 45 The study included 10 clinical trials and 1469 patients, with 708 patients in the probiotic supplementation group and 761 patients in the control group. Pooled ORs by intention-to-treat and perprotocol analyses in the probiotic supplementation group versus the control group were 2.066 (95% CI, 1.398-3.055) and 2.321 (95% CI, 1.715-3.142), respectively. The pooled OR of the incidence of total side effects was significantly decreased in the group given probiotics supplementation (OR = 0.305; 95% CI, 0.117-0.793). An association of a Lactobacillus and a Bifidobacterium with initial H. pylori eradication therapy in adults may have beneficial effects on the eradication rate and incidence of total side effects.
Many H. pylori eradication protocols involve the use of a PPI. A quadruple therapy has been proposed recently, including a combination of a PPI, bismuth subsalicylate (525 mg Â 4 daily), and 2 antibiotics, metronidazole (250 mg Â4 daily), and tetracycline (500 mg, Â 4 daily), for 10 to 14 days. 43 In any case, it is also fairly well recognised that a considerable impairment of the physiological gastric barrier typically mediated by luminal acidity may favour the establishment of H. pylori infection in the stomach. The extensive and prolonged use of a PPI could increase the incidence of H. pylori detection in gastric biopsy.
PPIs are among the most widely used drugs in the world and are generally regarded as effective also for longterm treatments. PPIs are the most potent inhibitors of gastric acid secretion available today and are mostly utilised with the aim of treating many conditions such as GERD, Barrett esophagus, peptic ulcer disease, dyspepsia, and Zollinger-Ellison syndrome. Although these agents are generally safe, a number of potential side effects have been described and a careful valuation of the risks and benefits of PPIs therapy is required in all patients being prescribed long-term treatment. Severe hypochlorhydria generated by PPI use leads to bacterial colonisation and increased susceptibility to enteric bacterial infection. Our study does not confirm the relationship between chronic PPI intake and a higher incidence of H. pylori infection. No statistically significant differences have been recorded between the 2 groups. The overall incidence of H. pylori infection was fairly low (20.6% in the PPI group vs. 25% in the control group). As expected in the light of the baseline results, 2-week supplementation with lactobacilli did not significantly reduce the percentage of subjects positive for H. pylori infection (5 of 29, 17.2%).
In any case, the baseline results concerning microbiological evaluations strengthened the hypothesis of a higher bacterial concentration in the stomach of subjects taking PPIs for at least 3 months. The total bacterial concentration was 4.40 log 10 higher in PPI-treated subjects compared with the normal population. In any case, coliforms and SRB, despite being significantly higher in PPI group, represented only a very little percentage of total bacteria, thus suggesting that other microbial groups play a pivotal role in overgrowth. Further studies are needed to investigate this aspect further.
Supplementation with the 4 microorganisms L. rhamnosus LR06, L. pentosus LPS01, L. plantarum LP01, and L. delbrueckii subsp. delbrueckii LDD01, administered in the form of chewable tablets, was able to significantly increase the number of total lactobacilli in the gastric juice and, at the same time, to decrease total bacteria, total coliforms, and SRB by <1 log 10 . A previous in vitro study has demonstrated the marked antagonistic activity of these lactobacilli towards 5 E. coli bacteria, the most important species within total coliforms, including the enterohemorrhagic O157:H7 strain, thus suggesting their possible use to prevent infections mediated by harmful or pathogenic microbes of this type. 46 These results are mostly consistent with the previous findings by Del Piano et al, 32 who used the same association of 4 lactobacilli combined with 60 mg of N-acetyl-cysteine (NAC) for 10 days in patients subjected to long-term treatment with PPIs (>12 mo) compared with short-termtreated subjects (from 3 to 12 mo) and with the normal population. In control subjects not taking PPIs, bacteria belonging to the Lactobacillus genus represented about 14% of total gastric microflora at baseline, whereas in people taking PPIs for >12 months, lactobacilli counted for only about 3% of total bacteria, therefore suggesting that the large majority of gastric microbiota was composed of other potentially harmful microbial groups. At the end of supplementation with the active formulation (10 days) in long-term-treated subjects, lactobacilli constituted 98% of total bacteria in gastric juice, and an increase in concentration compared with time 0 was recorded, although this was not statistically significant. The lack of statistical significance can be explained in the light of the relatively high concentration of lactobacilli at baseline (7.15 log 10 CFU/ mL compared with 3.85 log 10 CFU/mL in this study).
The mean concentration of total lactobacilli in gastric juice recorded in this study is comparable to the observations from the previous study by Del Piano et al 32 in subjects taking PPIs for 3 to 12 months (short-term), where this parameter was 5.01 log 10 CFU/mL. For some reasons, in our trial, the average total bacterial population was similar to the levels previously found in long-term-treated subjects, although total lactobacilli were lower and more typical of subjects taking PPIs for a shorter time span.
In any case, after 15 days of supplementation, only 23.66% of total bacterial population in the stomach was represented by lactobacilli, compared with 98.03% previously recorded in long-term-treated subjects after 10 days.
Two aspects may have exerted an influence on the ability of lactobacilli to colonise the stomach in this study:
the mode of supplementation with lactobacilli (chewable tablets instead of sachets), suggesting a possible higher persistence of such bacteria in the oral cavity compared with the previous study; the lack of N-acetyl-cysteine (NAC), a gelling ingredient able to mechanically hinder the adherence of harmful bacteria to the inner surface of the mucosa and, above all, to prevent possible formation of bacterial biofilms. Further investigation may be valuable in the future to better clarify the relationship between the duration of the treatment with any PPI and the modification of the composition of gastric microbiota, as well as the role exerted by the dosage form employed on the effectiveness of stomach colonisation by the same lactobacilli.
In conclusion, a significant and prolonged impairment of intragastric acidity is sufficient to induce significant bacterial overgrowth. This fact can contribute to increasing the risk of chronic and atrophic gastritis, food-borne infections, intestinal diseases, and profound alterations of the gut microbiota. The administration of an association of the specific strains L. rhamnosus LR06, L. pentosus LPS01, L. plantarum LP01, and L. delbrueckii subsp. delbrueckii LDD01 is able to significantly reduce bacterial overgrowth in the stomach after 15 days of oral supplementation, thus rapidly improving the gastric microbiota composition and restoring a protective barrier against harmful bacteria.
In the light of the very extensive use of PPIs all over the globe, concomitant oral supplementation with the 4 lactobacilli tested in this pilot study represents a very new strategy that could at least partially restore a physiological gastric barrier effect, therefore preventing or minimising the threat of food-borne gastrointestinal infections in the large segment of population undergoing chronic treatment with an acid suppressant drug. It is therefore possible to hypothesise a beneficial role for such lactobacilli in the clinical practice.
